IBSA Institut Biochimique SA

Founded in 1945 by Swiss biologists, IBSA Institut Biochimique SA develops pharmaceutical products intended to prevent and treat disease while advancing product safety and efficacy. Its therapeutic work spans reproductive medicine, endocrinology, pain and inflammation, bone and joint health, aesthetic medicine, dermatology, urogynecology, cardiometabolic medicine and respiratory care. The company also operates in consumer health, extending its portfolio across clinical and everyday health needs. This breadth positions IBSA across fields that address fertility, hormonal conditions, musculoskeletal care, skin health, respiratory conditions and metabolic health.

From its origins in Lugano, IBSA has grown into an international pharmaceutical group with products distributed in more than 90 countries across five continents and 20 subsidiaries. The group employs more than 2,500 people worldwide and serves principal markets across Europe, the Americas, the Middle East, the Far East and North Africa. Its governance framework combines a code of ethics with anti corruption guidelines and responsible sourcing standards. Supplier requirements address environmental, social and ethical conduct, while supply chain due diligence covers regulatory compliance, child labour standards and raw materials from conflict or high risk areas.